Ketamine Pharmacology: A Clinical Review for Providers

Ketamine's pharmacology is unusual. A drug that was developed as a dissociative anesthetic in 1962, classified as a veterinary sedative in the 1970s, and largely ignored by psychiatry for four decades now produces antidepressant responses in treatment-resistant patients within hours, an effect that existing receptor models of depression could not have predicted. The mechanistic story that has emerged since Berman's landmark 2000 trial is still being written, but the outlines are now clear enough to inform clinical practice: ketamine does not work the way SSRIs work, and understanding the distinction is what allows a prescriber to dose intelligently, manage side effects rationally, and have credible conversations with patients about what the molecule is actually doing in their brains.

NMDA Receptor Antagonism

The NMDA receptor is the entry point to everything else ketamine does. Whether you're thinking about antidepressant effect, dissociative experience, cardiovascular response, or cognitive side effects, the trail leads back to how and where ketamine binds glutamate's primary ionotropic receptor. Understanding this node is the difference between prescribing ketamine by recipe and prescribing it with mechanistic fluency.

Primary Mechanism of Action

Ketamine acts as a non-competitive antagonist at the NMDA receptor, glutamate's primary ionotropic receptor. It binds preferentially to extrasynaptic receptors that contain the NR2B subunit, and it does so through a voltage-dependent channel block rather than by competing with glutamate at the binding site. That single action is what sets the downstream glutamate modulation in motion.

The receptor selectivity is dose-dependent, which is why the anesthetic and psychiatric dose ranges produce such different clinical pictures. At the low doses used for depression, the effect is a relatively selective NMDA antagonism. As the dose climbs into the moderate range, the glutamate system is modulated more broadly. At high anesthetic doses, ketamine begins to interact with sigma, opioid, and monoamine sites as well, adding the receptor promiscuity that characterizes its use as a dissociative anesthetic.

Neuroplasticity and Synaptic Effects

The receptor blockade is, paradoxically, upstream of what actually produces the antidepressant effect. The clinically meaningful cascade is downstream: a disinhibition of cortical glutamate release, an AMPA-receptor-mediated signaling surge, and the activation of protein synthesis machinery that rebuilds synapses the depressed brain had allowed to atrophy. Most of the mechanistic interest in ketamine over the last decade has concentrated here, because this is the step that distinguishes ketamine's antidepressant mechanism from every prior class of antidepressant.

Within roughly thirty minutes of exposure, the mTOR signaling pathway is activated, driving the local protein synthesis that building a synapse requires. BDNF (brain-derived neurotrophic factor) is released and binds its TrkB receptor, the growth-factor signal that instructs neurons to build. New dendritic spines form and existing synapses strengthen, and over the following hours the prefrontal-cortex connectivity that chronic depression had allowed to atrophy begins to be restored. The reason this step draws most of the mechanistic interest is that it is where ketamine parts ways with every prior antidepressant class: monoamine drugs reach neuroplasticity only after weeks of indirect receptor adaptation, while ketamine triggers it directly and fast.

Clinical Pharmacokinetics

The pharmacokinetic profile is where the route-of-administration decision gets made, and each route produces a meaningfully different clinical experience. An IV infusion and a sublingual troche are not interchangeable tools delivering the same drug at different speeds; they produce different peak plasma concentrations, different brain exposure curves, and correspondingly different subjective and therapeutic effects. A clinician who understands this picks a route for a reason, not because it's what the clinic is set up to do.

Route-Specific Considerations

Intravenous ketamine has essentially complete bioavailability and near-immediate onset, with peak plasma concentrations one to five minutes after the infusion begins and rapid distribution into brain tissue. That speed is what makes it suited to acute treatment and clinic-based protocols, where a clinician is present for the whole arc of the effect.

Sublingual administration is a different drug experience, not the same drug delivered more slowly. Bioavailability drops to roughly 25 to 30% and absorption varies noticeably between patients; peak concentrations arrive at thirty to sixty minutes, and the effect is gentler in onset and longer in duration. That gentler curve is precisely what makes the route workable for supervised home-based treatment, where a sharp intravenous peak would be neither safe nor necessary.

Metabolism and Elimination

The metabolic pathway matters more than most prescribers realize because norketamine, ketamine's principal metabolite, is itself pharmacologically active and may contribute meaningfully to the sustained portion of the antidepressant effect. This also explains why hepatic impairment is a relative contraindication that requires dose adjustment rather than a theoretical concern that can be safely ignored.

Ketamine is cleared through the liver, primarily by N-demethylation to norketamine, with further hydroxylation and conjugation handling the remaining metabolites. The parent compound has a short elimination half-life of about 2.5 to 3 hours, but norketamine is not an inert breakdown product: it retains NMDA-antagonist activity of its own and likely contributes to the sustained portion of the antidepressant effect, which helps explain why the clinical benefit outlasts the parent drug's presence in plasma. Because the whole pathway runs through the liver, hepatic impairment shifts exposure enough to warrant real dose adjustment. It is a relative contraindication to be actively managed, not a theoretical concern to be waved away.

Clinical Efficacy Mechanisms

The question patients ask most often (how does this actually make me feel better?) does not have a short answer, because ketamine's antidepressant effect appears to operate through at least two temporally distinct mechanisms. The rapid onset effect, hours to days, is synaptic and reversible. The sustained effect, weeks to months, depends on structural changes that only consolidate if the neuroplastic window is actually used for therapeutic integration. Both tracks matter; neither alone explains the full clinical picture.

Antidepressant Effects

The rapid track is the cascade already described, compressed into hours: NMDA blockade, the glutamate surge and AMPA-receptor activation that follow, mTOR-mediated protein synthesis, and a restoration of synaptic plasticity that some patients register the same day. This track is reversible; on its own it would fade.

The sustained track is slower and structural, and it is what turns a good first week into a durable response. The new spines and synapses have to be stabilized into lasting network changes; the stress-response systems that chronic depression dysregulates, the HPA axis foremost, gradually renormalize; and there is accumulating evidence that ketamine dampens the neuroinflammatory signaling implicated in some treatment-resistant depression. The catch is that this consolidation depends on the plastic window actually being used, which is the biological argument for pairing dosing with active therapeutic work rather than dosing in isolation.

Anxiolytic Properties

Ketamine's effect on anxiety disorders, particularly generalized anxiety and PTSD, appears to operate through a parallel mechanism. The same disinhibition-and-plasticity story plays out in fear circuitry: ketamine dampens amygdala hyperactivity, restores the GABAergic tone that normally restrains it, and facilitates fear-extinction learning during the neuroplastic window, while the broader HPA-axis normalization lowers the baseline stress signal that keeps anxiety running hot. This is why combining ketamine with exposure-based psychotherapy during the 24 to 72 hours after a session produces outcomes that neither modality reliably achieves on its own.

Clinical Dosing Considerations

Dose selection in ketamine therapy is an exercise in finding the therapeutic window rather than maximizing exposure. Pushing the dose higher does not produce a proportionally larger antidepressant effect; it produces a larger dissociative experience with diminishing marginal benefit on mood outcomes and increasing side-effect burden. The dosing ranges below reflect the band within which the clinical literature has consistently observed response.

Therapeutic Window Optimization

For depression, the response band that recurs across the clinical literature sits at 0.5 to 1.0 mg/kg IV, or the sublingual equivalent, given two to three times weekly during induction and then spaced out toward maintenance as response consolidates. Within that band the dose is titrated to the individual, and the titration is guided by a specific judgment: find the point where the antidepressant benefit plateaus, because past it further dose mostly buys dissociation rather than mood improvement.

Chronic pain protocols generally run lower, often in the 0.3 to 0.5 mg/kg range, because the target there is less the mood cascade than ketamine's action on central sensitization and its anti-inflammatory effects. These are best used inside a multimodal pain plan rather than as monotherapy, and long courses require watching for tolerance in a way that the shorter depression protocols usually do not.

Safety and Monitoring Implications

The safety profile of ketamine is remarkably benign at therapeutic doses, which is both the feature that makes the treatment viable and the feature that lulls undertrained programs into skipping monitoring that should not be skipped. The adverse events are uncommon but not vanishingly so, and each of them is predictable from the underlying pharmacology: the sympathomimetic cardiovascular response is the sigma-receptor interaction and the catecholamine release; the dissociation is the NMDA blockade doing what it does.

Cardiovascular Effects

The cardiovascular response is sympathomimetic and dose-dependent: blood pressure and heart rate rise, peaking roughly fifteen to thirty minutes after administration and usually resolving within two to four hours as the drug redistributes. In a healthy patient this is a transient, self-limited bump that needs noting but not intervention. In a patient with meaningful cardiovascular risk it is the reason to take a baseline reading, monitor through the session, and set a blood-pressure threshold at which you hold the dose or abort. The mechanism is the same catecholamine release and sigma-receptor interaction that the pharmacology predicts, which is why the effect is reproducible enough to plan around.

Dissociative Effects Management

Dissociation is the aspect of ketamine that patients worry about most and that experienced clinicians worry about least. At therapeutic doses and in a properly prepared setting, mild to moderate dissociation is the expected experience, and in the treatment-resistant depression literature, there's suggestive evidence that it may correlate with better antidepressant response. Severe or distressing dissociation is a different clinical event and warrants dose reduction or route change rather than simply "pushing through."

Two operational rules follow from that distinction. First, separate the expected mild-to-moderate dissociation, which is part of the therapeutic mechanism and can be left to run its course, from distressing or poorly supported dissociation, which raises adverse-event risk and calls for dose reduction or a route change rather than a suggestion to push through. Second, most of what keeps dissociation therapeutic is decided before the dose is given: educating the patient in advance about what the experience will feel like so that it does not arrive as a fright, and shaping the environment (a quiet room, eye mask, chosen music, a trusted person or clinician present) so the experience has somewhere safe to unfold.

Conclusion

The pharmacology of ketamine is the strongest argument for treating it as a new class of psychiatric medicine rather than as a variation on existing antidepressants. A molecule that produces measurable antidepressant effect within hours through a receptor-level mechanism that existing drug development had entirely missed is a rare thing in psychiatry, and the clinical rigor it deserves matches that rarity. Prescribers who carry the mechanistic picture in their heads (who understand why the dose ranges are what they are, why the route matters, why the 72-hour integration window is biologically real) consistently produce better clinical outcomes than those who treat the drug as another SSRI with a weirder side-effect profile.

Refer a patient or get a curbside

If you have a patient who'd be a fit for ketamine and want to discuss a specific case before referring, the phone line is faster than email. For routine patient referrals, the eligibility screen below is the simplest path; we'll handle the rest and send you back a summary.

• Patient eligibility screen: tovanihealth.com/eligibility (5 minutes, FL, NJ, and CA residents)
• Clinician line: 561-468-6981 (curbside questions about a specific case welcome)
• What you get back: an evaluation summary with the treatment plan and any questions for your team after the consultation.

Benjamin Soffer, DO, Tovani Health

Related professional reading: SSRI vs ketamine pharmacological comparison, evidence-based outcomes review, clinical protocols and patient selection, psychiatric consultation protocols.